Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
159 days ago
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
193 days ago
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
340 days ago
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
921 days ago
Dollar Rises Against Major Counterparts On Strong Economic Data
The U.S. dollar firmed against its major counterparts on Tuesday on bets the Federal Reserve will slowdown its rate cut moves after data showed an improvement in the nation's service sector activity in the month of December. Higher bond yields contributed as well to greenback's rise.
RTTNews
|
5h 33min ago
Indian Economy To Expand 6.4% In FY25, Weakest In 4 Years: Govt Estimate
India's economy is set to grow at the slowest pace in 4 years in the fiscal year 2024-25, initial estimates from the government showed on Tuesday. Gross domestic product is expected to grow 6.4 percent in the financial year ending March 31 following an 8.2 percent expansion in the previous fiscal.
RTTNews
|
7h 3min ago
Swiss Market Ends On Strong Note After Inflation Data
The Switzerland market closed on a strong note on Tuesday with stocks shrugging off early weakness and gaining in strength as the day progressed. Data showing a slowdown in consumer price inflation aided sentiment.
RTTNews
|
8h 33min ago
European Stocks Close Higher As Markets React To Economic Data
European stocks closed mostly higher on Tuesday despite struggling a bit early on in the session, as investors digested a slew of regional economic data and continued to bet on more monetary easing by central banks in the first quarter of 2025.
RTTNews
|
8h 49min ago
